In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of C4 Therapeutics Inc (NASDAQ: CCCC) was $6.32 for the day, down -1.71% from the previous closing price of $6.43. In other words, the price has decreased by -$1.71 from its previous closing price. On the day, 0.78 million shares were traded. CCCC stock price reached its highest trading level at $6.53 during the session, while it also had its lowest trading level at $6.07.
Ratios:
Our analysis of CCCC’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.09 and its Current Ratio is at 5.09. In the meantime, Its Debt-to-Equity ratio is 0.28 whereas as Long-Term Debt/Eq ratio is at 0.25.
On December 13, 2023, Stifel Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $2 to $12.
Credit Suisse Upgraded its Underperform to Neutral on February 24, 2023, whereas the target price for the stock was revised from $12 to $10.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CCCC now has a Market Capitalization of 438214912 and an Enterprise Value of 242533600. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.92 while its Price-to-Book (P/B) ratio in mrq is 1.76. Its current Enterprise Value per Revenue stands at 8.256 whereas that against EBITDA is -2.115.
Stock Price History:
Over the past 52 weeks, CCCC has reached a high of $11.88, while it has fallen to a 52-week low of $1.06. The 50-Day Moving Average of the stock is 9.89%, while the 200-Day Moving Average is calculated to be 5.54%.
Shares Statistics:
CCCC traded an average of 1.57M shares per day over the past three months and 1009580 shares per day over the past ten days. A total of 60.47M shares are outstanding, with a floating share count of 57.28M. Insiders hold about 17.42% of the company’s shares, while institutions hold 82.28% stake in the company. Shares short for CCCC as of 1723680000 were 10503384 with a Short Ratio of 6.68, compared to 1721001600 on 11625527. Therefore, it implies a Short% of Shares Outstanding of 10503384 and a Short% of Float of 18.42.
Earnings Estimates
At present, 7.0 analysts are actively evaluating the performance of C4 Therapeutics Inc (CCCC) in the stock market.The consensus estimate for the next quarter is -$0.39, with high estimates of -$0.2 and low estimates of -$0.64.
Analysts are recommending an EPS of between -$1.18 and -$1.7 for the fiscal current year, implying an average EPS of -$1.48. EPS for the following year is -$1.64, with 8.0 analysts recommending between -$1.26 and -$2.36.
Revenue Estimates
A total of 7 analysts have provided revenue estimates for CCCC’s current fiscal year. The highest revenue estimate was $46M, while the lowest revenue estimate was $15M, resulting in an average revenue estimate of $28.43M. In the same quarter a year ago, actual revenue was $20.76M
